Biology subjects

Vinkers, C. H.

Publications and source records attributed to Vinkers, C. H..

3 recordsLinked to original sources

bioRxiv2018

microRNA regulation of persistent stress-enhanced memory

Disruption of persistent, stress-associated memories is relevant for treating posttraumatic stress disorder (PTSD) and related syndromes, which develop in a subset of individuals following a traumatic event. Using a stress-enhanced fear learning protocol that results in differential susceptibility in inbred mice, we integrated small-RNA sequencing with quantitative proteomics on basolateral amygdala tissue collected one month after training. We identified persistently changed microRNAs, including mir-135b-5p, and predicted target proteins associated with PTSD-like heightened fear expression. Functional manipulations of mir-135b-5p bidirectionally modulated stress-associated memory. mir-135b-5p is expressed in human amygdala and its passenger strand was elevated in serum from a well-characterized military PTSD cohort. miR-135b-5p is a therapeutic target for dampening persistent, stress-enhanced memory and its passenger strand a potential biomarker for responsivity to a mir-135-based therapeutic.\n\nOne Sentence Summarymir-135 can be manipulated to weaken persistent, stress-associated memory and serve as a biomarker of PTSD.

neuroscience↗

bioRxiv2017

Statistical power of clinical trials has increased whilst effect size remained stable: an empirical analysis of 137 032 clinical trials between 1975-2017

BackgroundBiomedical studies with low statistical power are a major concern in the scientific community and are one of the underlying reasons for the reproducibility crisis in science. If randomized clinical trials, which are considered the backbone of evidence-based medicine, also suffer from low power, this could affect medical practice.\n\nMethodsWe analysed the statistical power in 137 032 clinical trials between 1975 and 2017 extracted from meta-analyses from the Cochrane database of systematic reviews. We determined study power to detect standardized effect sizes according to Cohen, and in meta-analysis with p-value below 0.05 we based power on the meta-analysed effect size. Average power, effect size and temporal patterns were examined.\n\nResultsThe number of trials with power [≥]80% was low but increased over time: from 9% in 1975-1979 to 15% in 2010-2014. This increase was mainly due to increasing sample sizes, whilst effect sizes remained stable with a median Cohens h of 0.21 (IQR 0.12-0.36) and a median Cohens d of 0.31 (0.19-0.51). The proportion of trials with power of at least 80% to detect a standardized effect size of 0.2 (small), 0.5 (moderate) and 0.8 (large) was 7%, 48% and 81%, respectively.\n\nConclusionsThis study demonstrates that sufficient power in clinical trials is still problematic, although the situation is slowly improving. Our data encourages further efforts to increase statistical power in clinical trials to guarantee rigorous and reproducible evidence-based medicine.

epidemiology↗

bioRxiv2017

Comprehensive Pathway Analyses Of Schizophrenia Risk Loci Point To Dysfunctional Postsynaptic Signaling

Large-scale genome-wide association studies (GWAS) have implicated many low-penetrance loci in schizophrenia. However, its pathological mechanisms are poorly understood, which in turn hampers the development of novel pharmacological treatments. Pathway and gene set analyses carry the potential to generate hypotheses about disease mechanisms and have provided biological context to genome-wide data of schizophrenia. We aimed to examine which biological processes are likely candidates to underlie schizophrenia by integrating novel and powerful pathway analysis tools using data from the largest Psychiatric Genomics Consortium schizophrenia GWAS (N = 79 845) and the most recent 2018 schizophrenia GWAS (N = 105 318). By applying a primary unbiased analysis (Multi-marker Analysis of GenoMic Annotation; MAGMA) to weigh the role of biological processes from the MSigDB database, we identified enrichment of common variants in synaptic plasticity and neuron differentiation gene sets. We supported these findings using MAGMA, Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA) and Interval Enrichment Analysis (INRICH) on detailed synaptic signaling pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and found enrichment in mainly the dopaminergic and cholinergic synapses. Moreover, shared genes involved in these neurotransmitter systems had a large contribution to the observed enrichment, protein products of top genes in these pathways showed more direct and indirect interactions than expected by chance, and expression profiles of these genes were largely similar among brain tissues. In conclusion, we provide strong and consistent genetics and protein-interaction informed evidence for the role of postsynaptic signaling processes in schizophrenia, opening avenues for future translational and psychopharmacological studies.

genetics↗